At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 151 enrolled
Drug / intervention
Ranibizumab 0.3 mg +2 moredrug
Likely dose
Ranibizumab 0.3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-masked, Multi-center, Phase II Study Assessing the Safety and Efficacy of Two Concentrations of Ranibizumab (Intravitreal Injections) Compared With Non-treatment Control for the Treatment of Diabetic Macular Edema With Center Involvement
In Brief
A Phase 2 clinical trial evaluating Ranibizumab 0.3 mg, Ranibizumab 0.5 mg, and 1 other intervention for Diabetic Macular Edema. Completed, enrolled 151 participants across 1 site.
Detailed Summary
This study evaluated the safety and efficacy of ranibizumab on retinal edema and visual acuity in patients with diabetic macular edema with center involvement.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema
CountriesSwitzerland
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2005
First PostedJan 2006
Primary CompletionJun 2008
TodayJul 2026
First PostedJan 31, 2006
Enrollment StartOct 1, 2005
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 20.4 years ago
Interventions
Ranibizumab 0.3 mgdrug
6 mg/ml ranibizumab solution for intravitreal injection
Ranibizumab 0.5 mgdrug
10 mg/ml ranibizumab solution for intravitreal injection
Sham injectiondrug
Non-treatment control for sham intravitreal injection.